Skip to main content
OpenTrials
Completed

NCT Number: NCT05595538

Use of Multiple Doses of Convalescent Plasma in Mechanically Intubated Patients With COVID-19

This study will assess the feasibility and safety of administering multiple doses of convalescent plasma to Covid-19 positive patients admitted to the Intensive Care Unit (ICU) receiving mechanical ventilation. Donor plasma will be obtained from Covid-19 recovered patients. All plasma used in this protocol will be collected following the guidelines issued by the Food and Drug Administration (FDA) and the Ministry of Health in Panama.

Every patient recruited will receive one or two plasma units infused on days 0, 2, 4, 6, and 8. The primary objective of this study is feasibility. Feasibility will be assessed based on the proportion of subjects who consent and receive at least one dose of convalescent plasma more than once. The investigators will evaluate the safety and feasibility of this study by accounting for any related adverse event.

The secondary study endpoints are overall survival at days 14, 28, and 60 after the first dose of convalescent plasma. Respiratory status and overall clinical status will be reviewed during follow-up until day nine and on days 14, 28, and 60.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Coronaviridae Infections Coronavirus Infections Critical Illness Disease Attributes Infections Lung Diseases Nidovirales Infections Pathologic Processes Pathological Conditions, Signs and Symptoms Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

1. Complejo Hospitalario Metropolitano Arnulfo Arias Madrid, Caja de Seguro Social

Panama City, Panama

About this study

From historical and anecdotal data on convalescent plasma, it seems its administration is safe in cases of coronavirus infection. Now, the high mortality of COVID-19, particularly in elderly and vulnerable persons such as critically ill patients, suggests that the benefits of its use in those at high risk for death outweigh the risks. However, for all cases where convalescent plasma administration is considered, a risk-benefit assessment must be conducted to assess individual variables.

This study proposed the follow-up of 30 intubated patients due to COVID-19 who have been admitted to the ICU and have consented to receive five doses of one or two units of convalescent plasma.

Every patient will have a follow-up from the consent day to day 60. The study team will monitor and record: vital signs, daily ventilatory requirements, and assessment of clinical status, including new medical conditions and adverse events.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age or older
  • Hospitalized with COVID-19 respiratory symptoms and confirmation via COVID-19 SARS-CoV-2 Real Time-polymerase chain reaction(PCR) testing.
  • Subject or proxy (including by phone) is willing and able to provide written or digital informed consent and comply with all protocol requirements.
  • Intubated
  • Consent to storage of specimens for future testing.

Exclusion criteria

  • Contraindication to transfusion (severe volume overload, history of anaphylaxis to blood products).
  • Severe multi-organ failure, and hemodynamic instability.
  • Other documented uncontrolled infections.
  • Severe disseminated intravascular coagulopathy (DIC) needing factor replacement, FreshFrozen Plasma, cryoprecipitate.
  • On dialysis.
  • Active intracranial bleeding.
  • Clinically significant myocardial ischemia.

Treatment and study plan

Multiple doses of anti-SARS-CoV-2 Convalescent Plasma

Biological

SARS-CoV-2 Convalescent Plasma(1-2 units; ~300-600 mL with the presence of IgG anti-SARS-CoV-2.

Other names: COVID-19 Convalescent Plasma

Primary outcomes

  1. Percentage of participants who received at least one unit more than one day

    Time frame: 8 days

    Transfusion of multiple doses (up to 5 doses) of 300-600 ml of convalescent plasma from COVID-19

Secondary outcomes

  1. Development of plasma transfusion reaction

    Time frame: 8 days

    presence of any sign or symptoms of plasma transfusion reaction (TACO, TRALI, fever, rash)

  2. Overall Survival

    Time frame: 60 days

    overall survival up to day 60

  3. oxygen Support

    Time frame: 60 days

    type of ventilatory support by days 9, 14, 28, and 60. The options for types of oxygen support are: Mechanical Ventilation, Non/invasive ventilation, and no support needed.

  4. Clinical Status

    Time frame: 60 days

    Change in 7-point ordinal clinical deterioration scale pre-transfusion to Days 1, 3, 7, 9, 14, 28 and 60 post-transfusion. The 7-point ordinal scale measured by: 7-death, 6-ICU patient who requires extracorporeal membrane oxygenation (ECMO) or mechanical ventilation; 5-ICU patient, do not requires ECMO or mechanical ventilation; 4 -hospitalization and requires supplemental oxygen; 3- hospitalization without supplemental oxygen; 2- limitation of activities, discharge from hospital 1- no limitation of activities, discharge from hospital.

Sponsors and collaborators

Lead sponsor

Hospital Regional Dr. Rafael Estévez

Other

Collaborators

  • Complejo Hospitalario Dr. Arnulfo Arias Madrid
  • Hospital Punta Pacífica, Pacífica Salud
  • Hospital Santo Tomas
  • Insituto Conmemorativo Gorgas de Estudios para la Salud
  • Institute of Scientific Research and High Technology Services (INDICASAT AIP)
  • Sistema Nacional de Investigación de Panamá
  • Sociedad Panameña de Hematología
  • University of Panama

Registry information

Official study title

A Feasibility Study Assessing the Safety of Multiple Doses of Anti-SARS-CoV-2 Plasma in Mechanically Ventilated Intubated Patients With Respiratory Failure Due to Coronavirus Disease (COVID-19)

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Oct 27, 2022
Registry last updated
Oct 27, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.